| 1564 |
National Cancer Institute |
Html |
en |
Laryngeal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of laryngeal cancer. |
| treatment | 0.456448 |
| cancer treatment | 0.208981 |
| vocal cords | 0.463035 |
| Laryngeal Cancer Treatment | 0.208444 |
| NCI-supported cancer | 0.201905 |
| cancer cells | 0.32099 |
| stage laryngeal cancer | 0.221553 |
| body | 0.20156 |
| chemotherapy | 0.227934 |
| PDQ cancer information | 0.235798 |
| larynx | 0.286996 |
| clinical trial search | 0.245354 |
| Hyperfractionated radiation therapy | 0.214818 |
| laryngeal cancer spreads | 0.200731 |
| National Cancer Institute | 0.254821 |
| laryngeal cancer | 0.644668 |
|
| clinical trials | 0.596105 |
| metastatic laryngeal cancer | 0.202273 |
| cancer information summary | 0.213869 |
| clinical trial | 0.439358 |
| Recurrent laryngeal cancer | 0.222324 |
| new treatment | 0.207333 |
| patients | 0.231814 |
| neck | 0.206846 |
| original tumor | 0.252057 |
| cancer clinical trials | 0.262761 |
| stage | 0.247854 |
| lymph nodes | 0.238789 |
| lymph node | 0.41143 |
| radiation therapy | 0.83207 |
| cancer | 0.992267 |
|
CLICK HERE |
| 1665 |
National Cancer Institute |
Html |
null |
Last Days of Life (PDQ®)–Patient Version |
Expert-reviewed information summary about care during the last days to last hours of life, including common symptoms, ethical dilemmas that may arise, and the role of the oncologist in caring for patients and their families during this time. |
|
|
CLICK HERE |
| 1689 |
National Cancer Institute |
Html |
en |
Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood central nervous system germ cell tumors. |
| craniospinal irradiation | 0.568926 |
| intracranial germinoma | 0.542559 |
| survival rates | 0.505415 |
| excellent survival rates | 0.497286 |
| endodermal sinus tumor | 0.492396 |
| germ cell tumor | 0.543477 |
| chemotherapy | 0.510034 |
| reduced-volume radiation therapy | 0.492394 |
| ifosfamide based chemotherapy | 0.484152 |
| Tumors Treatment Overview | 0.506029 |
| primordial germ cells | 0.489907 |
| focal radiation therapy | 0.518434 |
| pure germinomas | 0.484971 |
| Radiat Oncol Biol | 0.492523 |
| tumor markers | 0.56413 |
| radiation therapy doses | 0.490668 |
| CNS germ cell | 0.55586 |
| tumor markers AFP | 0.505621 |
| cerebrospinal tumor markers. | 0.502663 |
| conventional whole-brain irradiation | 0.482504 |
| whole-ventricular radiation therapy | 0.492409 |
| CSF AFP levels | 0.509387 |
| nongerminomatous germ cell | 0.513106 |
| cell tumor study | 0.490435 |
| yolk sac tumor | 0.491117 |
|
| germ cell theory | 0.506108 |
| common solid tumor | 0.502347 |
| germinomatous germ cell | 0.4915 |
| primary chemotherapy | 0.487412 |
| radiation therapy | 0.751812 |
| et al. | 0.485468 |
| Low-dose craniospinal irradiation | 0.484891 |
| CNS GCTs | 0.523584 |
| whole-ventricle radiation therapy | 0.491449 |
| SIOP CNS GCT | 0.490345 |
| brain tumor treatment | 0.516207 |
| primary brain tumors | 0.544753 |
| neoadjuvant chemotherapy results | 0.491554 |
| Pediatr Blood Cancer | 0.568832 |
| response-based radiation therapy | 0.486149 |
| radiation treatment volume | 0.488339 |
| boost radiation therapy | 0.486976 |
| nervous system tumors | 0.483298 |
| Brain Tumor Study | 0.49693 |
| Oncol Biol Phys | 0.49429 |
| specific chemotherapy regimen | 0.484857 |
| intracranial germ cell | 0.58985 |
| germ cell tumors | 0.911962 |
| radiation therapy fields | 0.485192 |
|
CLICK HERE |
| 1786 |
National Cancer Institute |
Html |
es |
Linfedema (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del linfedema. |
| siguientes áreas | 0.436931 |
| causa hinchazón | 0.778344 |
| pequeña cantidad | 0.464081 |
| pequeños cortes | 0.452311 |
| siguientes abordajes | 0.459419 |
| PDQ Linfedema | 0.618416 |
| sección información | 0.436578 |
| largo plazo | 0.580542 |
| protector solar | 0.453778 |
| sección manejo | 0.432902 |
| National Cancer Institute | 0.432858 |
| ropa flojos | 0.450402 |
| siguientes riesgos | 0.424859 |
|
| Instituto Nacional | 0.463187 |
| siguientes problemas | 0.490486 |
| linfedema atrapa | 0.967072 |
| Physician Data Query | 0.535003 |
| Estados Unidos | 0.442188 |
| estadio iii | 0.728645 |
| siguientes medidas | 0.469803 |
| linfa circula | 0.531655 |
| linfedema.ampliar anatomÃa | 0.480452 |
| siguientes pruebas | 0.475048 |
| uñas ayuda | 0.454713 |
| baja potencia | 0.433231 |
|
CLICK HERE |
| 1958 |
National Cancer Institute |
Html |
es |
Tratamiento del retinoblastoma (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del retinoblastoma en niños. |
| siguientes procedimientos | 0.348249 |
| células madre | 0.681334 |
| células madre ayuda | 0.327411 |
| pequeña cantidad | 0.314739 |
| quimioterapia regional.También | 0.356888 |
| siguientes especialistas | 0.315369 |
| rayos x | 0.316905 |
| huesos.ampliar exploración | 0.316446 |
| sección información | 0.311156 |
| ondas sonoras | 0.352613 |
| efectos tardÃos | 0.419814 |
| PDQ Efectos tardÃos | 0.340519 |
| estadio iva | 0.318526 |
| tejidos cercanos.ampliar radioterapia | 0.346215 |
| quimioterapia sistémica | 0.959376 |
| lÃquido cefalorraquÃdeo | 0.342894 |
| National Cancer Institute | 0.310552 |
|
| retinoblastoma causa efectos | 0.427797 |
| estadios iiia | 0.316715 |
| Instituto Nacional | 0.318729 |
| PDQ Tratamiento | 0.331936 |
| determinados cambios | 0.322309 |
| International Retinoblastoma Staging | 0.571406 |
| Drugs Approved | 0.312346 |
| gen rb1 | 0.821065 |
| Physician Data Query | 0.339103 |
| sistema nervioso central | 0.324254 |
| posibles efectos | 0.313593 |
| Retinoblastoma Staging System | 0.572567 |
| siguientes situaciones | 0.322957 |
| placa ayuda | 0.311711 |
| haz láser | 0.317188 |
| siguientes pruebas | 0.320835 |
|
CLICK HERE |
| 2023 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de seno (mama) (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de mama y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| Risk Assessment Tool | 0.639814 |
| enfermedad benigna | 0.724402 |
| voluntarios sanos | 0.550874 |
| siguientes afecciones | 0.583572 |
| posibles daños | 0.559702 |
| vÃa oral | 0.551992 |
| largo plazo | 0.555083 |
| carcinoma lobulillar situ | 0.643038 |
| National Cancer Institute | 0.566999 |
| vitamina a | 0.552574 |
| siguientes riesgos | 0.550628 |
| Instituto Nacional | 0.618668 |
| protección ayuda | 0.699167 |
|
| Physician Data Query | 0.746401 |
| Estados Unidos | 0.579171 |
| suficiente ejercicio | 0.906195 |
| siguientes caracterÃsticas | 0.59401 |
| prevención revisa | 0.554009 |
| PDQ Prevención | 0.599371 |
| Menor exposición | 0.569365 |
| siguientes formas | 0.705774 |
| pequeñas llamadas lobulillos | 0.645602 |
| Mayor edad | 0.567138 |
| genes brca1 | 0.883252 |
| conductos.ampliar anatomÃa | 0.589939 |
| siguientes sumarios | 0.661886 |
|
CLICK HERE |
| 2115 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de hígado (hepatocelular) (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre factores que influirían en el riesgo de presentar cáncer hepatocelular y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| chronic hepatitis b | 0.391786 |
| chronic hepatitis c | 0.392121 |
| available online | 0.329517 |
| American Cancer Society | 0.362594 |
| tt virus dna | 0.321147 |
| largo plazo | 0.314356 |
| with hepatocellular carcinoma | 0.362577 |
| hepatitis e | 0.456465 |
| CHC agudo | 0.334135 |
| denominación hepatitis no-A | 0.402257 |
| hepatocellular carcinoma | 0.818192 |
| Concurrent hepatitis | 0.385001 |
| Instituto Nacional | 0.321684 |
| Qidong hepatitis | 0.385791 |
| patients with chronic | 0.340288 |
| hÃgado llamada cirrosis | 0.31992 |
| hepatitis nanb | 0.397414 |
| risk factors | 0.334046 |
| hepatitis b | 0.815878 |
| hepatitis c | 0.64216 |
| Estados Unidos | 0.516836 |
| virus hepáticos forma | 0.324783 |
| Universal hepatitis | 0.404867 |
| Spanish patients with | 0.316748 |
| PDQ Prevención | 0.319178 |
|
| patients with | 0.420437 |
| carcinoma among patients | 0.322468 |
| SEER Cancer Statistics | 0.314302 |
| Rizzetto M | 0.316034 |
| Infect Dis | 0.316615 |
| virus carriers with | 0.326772 |
| natural history | 0.314507 |
| Ningún virus | 0.321223 |
| hepatocelular factores causales | 0.320088 |
| Viral Hepatitis FAQs | 0.396943 |
| National Cancer Institute | 0.335176 |
| La hepatitis | 0.94804 |
| Chang MH | 0.316907 |
| viral hepatitis | 0.515061 |
| Yuan JM | 0.316452 |
| GB virus | 0.317604 |
| correlate with expression | 0.314623 |
| Long-term phlebotomy with | 0.314798 |
| Liver Int | 0.354023 |
| Hepatocellular carcinoma without | 0.326846 |
| chronic hepatitis | 0.450334 |
| hepatitis aguda | 0.53174 |
| hepatitis tipos | 0.394509 |
| virus rna | 0.317794 |
|
CLICK HERE |
| 3424 |
National Cancer Institute |
Html |
es |
Informes de patología |
Hoja informativa que describe el tipo de información que puede aparecer en un informe de patología, el cual contiene los resultados de la examinación visual y microscópica del tejido extirpado durante una biopsia o cirugía. |
| página del nci | 0.749066 |
| cromosoma filadelfia | 0.760969 |
| ¿Cuánto tiempo | 0.803391 |
| leucemia mielógena | 0.766464 |
| tipo southern | 0.748591 |
|
| Detecta fragmentos | 0.751768 |
| simple vista | 0.960274 |
| Instituto Nacional | 0.833257 |
| cuello uterino | 0.83163 |
|
CLICK HERE |
| 3570 |
National Cancer Institute |
Html |
en |
The NCI Outstanding Investigator Award (R35) |
The NCI Outstanding Investigator Award (OIA) supports investigators with outstanding records of productivity in cancer research by providing extended funding stability and encouraging investigators to continue or embark on projects of unusual potential in cancer research. |
| direct costs | 0.516422 |
| projects | 0.339999 |
| person months effort | 0.510514 |
| OIA | 0.56501 |
| greater risks | 0.517599 |
| Institution | 0.338577 |
| outstanding productivity | 0.586579 |
| cancer research | 0.764353 |
| funded investigators | 0.583615 |
|
| Award | 0.340824 |
| NCI Outstanding Investigator | 0.903247 |
| outstanding records | 0.61157 |
| recipient | 0.352813 |
| Principal Investigator | 0.547103 |
| PI | 0.388963 |
| substantial time | 0.526242 |
| NCI grant | 0.541618 |
| salary support | 0.509963 |
|
CLICK HERE |
| 17242 |
National Cancer Institute |
Html |
en |
National Cryo-Electron Microscopy Facility Team Members |
The National Cryo-Electron Microscopy Facility team is responsible for the operational activities of NCEF. Find team member bios and a list of NCEF working group members. |
| strategic oversight | 0.549362 |
| Lab Advisory Committee | 0.88433 |
| Frederick National Lab | 0.883241 |
| NCEF Senior Microscopist | 0.757617 |
| Molecular Virology | 0.5561 |
| government contract projects | 0.639164 |
| cancer researchers. | 0.551348 |
| Piermaria J. Oddone | 0.648956 |
| Thomas Edwards | 0.534246 |
| cryo-EM laboratories | 0.7289 |
| Grant J. Jensen | 0.61562 |
| advisory committee members | 0.653176 |
| research expertise | 0.57237 |
| PMP certification | 0.536505 |
| structural biology | 0.656766 |
| Advanced Computer Studies | 0.527736 |
| L. Mario Amzel | 0.617619 |
| NCEF Scientific Project | 0.683141 |
| Biophysics Section | 0.560804 |
| Stephen C. Harrison | 0.611643 |
| structural studies | 0.552951 |
| resolution cryo-electron microscopy | 0.682528 |
| structural biology communities | 0.646732 |
| academic research | 0.551259 |
| Hopkins University School | 0.630222 |
|
| Steven J. Ludtke | 0.641874 |
| cryo-EM services | 0.763943 |
| Senior Investigator | 0.530394 |
| Physical Biochemistry | 0.552108 |
| Infectious Disease research | 0.655231 |
| Sriram Subramaniam | 0.554662 |
| Angela M. Gronenborn | 0.615627 |
| Ph.D | 0.61505 |
| Hong Zhou | 0.531963 |
| core team | 0.649969 |
| structural analysis | 0.55203 |
| Ulrich Baxa | 0.572356 |
| Edward H. Egelman | 0.618207 |
| Cancer Research | 0.549211 |
| NCEF Microscopist | 0.616796 |
| National Lab Advisory | 0.882693 |
| adjunct faculty appointments | 0.637399 |
| strong background | 0.529367 |
| Cell Biology | 0.534261 |
| Project Management | 0.649065 |
| National Cryo-EM Facility | 0.904008 |
| Helen Wang | 0.529981 |
| single particle cryo-EM | 0.833864 |
| electron tomography | 0.5462 |
|
CLICK HERE |